Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround

Core Viewpoint - PDS Biotechnology (PDSB) is experiencing significant selling pressure, having declined 35.7% over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) for PDSB is currently at 22.34, indicating that the heavy selling may be exhausting itself, suggesting a possible bounce back towards equilibrium in supply and demand [3] - A stock is generally considered oversold when its RSI falls below 30, which can signal potential entry opportunities for investors looking to benefit from a rebound [2] Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts to raise earnings estimates for PDSB, with a 4.9% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [4] - PDSB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further indicating a potential turnaround [4]